Whole Genome-Based Liquid Biopsy Assay Commercialization, Collaboration Commences
Personalis, Inc. has partnered with Tempus to commercialize NeXT Personal, an ultra-sensitive, whole genome-based liquid biopsy assay.
Read MorePosted by Chris Wolski | May 31, 2024 | Immunoassay Reagents & test Kits |
Personalis, Inc. has partnered with Tempus to commercialize NeXT Personal, an ultra-sensitive, whole genome-based liquid biopsy assay.
Read MorePosted by Chris Wolski | May 27, 2024 | Lung Cancer |
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read MorePosted by Andy Lundin | May 21, 2024 | Sequencing Systems |
Foundation Medicine launched a tissue-based RNA sequencing test in the U.S. for the detection of cancer-related fusions across 318 genes.
Read MorePosted by Andy Lundin | Mar 21, 2024 | Lung Cancer |
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read MorePosted by Andy Lundin | Feb 22, 2024 | Diagnostic Technologies |
A research project supported by the National Institutes of Health has developed a tool to rapidly and inexpensively diagnose sarcoidosis.
Read More